The first product containing bevacizumab intended for the treatment of wet age-related macular degeneration could well be on its way to an EU marketing authorization if the European Medicines Agency gives it the green light this week.
Ophthalmic bevacizumab is up for an opinion from the EMA’s human drugs committee, the CHMP, during its latest monthly








